Entasis Therapeutics Appoints Dr. Howard Mayer to Board of Directors
August 05 2019 - 4:01PM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced the appointment of
Howard Mayer, M.D to its board of directors, effective immediately.
“Dr. Mayer has a strong track record in
executive management at several large pharmaceutical companies such
as Pfizer, Bristol-Myers Squibb, Merck KGaA and Shire and his skill
set is highly complementary with the Entasis board,” said Manos
Perros, President and Chief Executive Officer of Entasis. “He
brings a wealth of experience leading and executing clinical
programs, particularly in the infectious disease space. We are
pleased to have Dr. Mayer as a resource and look forward to drawing
on his invaluable knowledge as we advance our late-stage pipeline
towards commercialization.”
Dr. Mayer has over 25 years of medical, clinical
and executive experience in the life sciences industry. Dr. Mayer
was Senior Vice President, Chief Medical Officer and Global Head of
R&D, Neuroscience Division at Shire Pharmaceuticals. While at
Shire, he also served as Senior Vice President and Head of Clinical
Development. Prior to joining Shire, Dr. Mayer worked for EMD
Serono, a division of Merck KGaA, where he served as Chief Medical
Officer. He also previously held various executive positions in
clinical development at Pfizer Inc. and Bristol-Myers Squibb. He
currently serves on the Board of Directors for Genocea Biosciences
and Autism Speaks in New England. Dr. Mayer obtained his B.A. from
the University of Pennsylvania and his M.D. from Albert Einstein
College of Medicine in New York. He completed an internship and
residency at Mount Sinai Hospital and an Infectious Diseases
fellowship at New England Deaconess Hospital and Harvard Medical
School.
Dr. Mayer added, “I’m excited to join an
innovative company with the potential to make a fundamental
difference in the antimicrobial space. Entasis has a strong
pipeline of pathogen-targeted medicines and I look forward to
bringing my experience and insights to Entasis as they finalize
development and prepare for commercialization of these
differentiated products.”
About EntasisEntasis is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel antibacterial products
to treat serious infections caused by multidrug-resistant
Gram-negative bacteria. Entasis’ pathogen-targeted design platform
has produced a pipeline of product candidates, including
sulbactam-durlobactam (targeting Acinetobacter
baumannii infections), zoliflodacin (targeting Neisseria
gonorrhoeae), and ETX0282CPDP
(targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information,
visit www.entasistx.com.
Entasis Company ContactKyle
DowEntasis Therapeutics(781) 810-0114kyle.dow@entasistx.com
Investor Relations Contacts
Tram Bui / Janhavi Mohite The Ruth Group (646) 536-7035 / 7026
tbui@theruthgroup.com jmohite@theruthgroup.com
Media ContactKirsten ThomasThe
Ruth Group(508) 280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024